Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

PHASE4CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

July 5, 2016

Primary Completion Date

July 25, 2018

Study Completion Date

July 25, 2018

Conditions
Glaucoma, Open-AngleNormal Tension Glaucoma
Interventions
DRUG

brimonidine tartrate/timolol malate Ophthalmic Solution

One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months

DRUG

bimatoprost ophthalmic solution 0.01%

Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed

Trial Locations (9)

13619

Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do

35015

Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon

42415

Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu

49241

Pusan National University Hospital, Pusan National University School of Medicine, Busan

61469

Chonnam National University Hospital, Chonnam National University Medical School, Gwangju

03080

Seoul National University Hospital, Seoul National University College of Medicine, Seoul

03181

Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul

06591

Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul

07301

Kim's Eye Hospital, Konyang University College of Medicine, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY